Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities
Author:
Funder
Fondazione Oncologia Niguarda Onlus
Publisher
Elsevier BV
Subject
Radiology Nuclear Medicine and imaging,Oncology,General Medicine
Reference108 articles.
1. Cancer statistics, 2019;Siegel;CA Cancer J Clin,2019
2. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Krieken V, H J, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27:1386–422. https://doi.org/10.1093/annonc/mdw235.
3. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial;Venook;JAMA,2017
4. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial;Ciardiello;Ann Oncol,2014
5. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer;Douillard;N Engl J Med,2013
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Bridging pyrimidine hemicurcumin and Cisplatin: Synthesis, coordination chemistry, and in vitro activity assessment of a novel Pt(II) complex;Journal of Inorganic Biochemistry;2024-11
2. Isocitrate dehydrogenases 2-mediated dysfunctional metabolic reprogramming promotes intestinal cancer progression via regulating HIF-1A signaling pathway;International Immunopharmacology;2024-10
3. AKR1C1 interacts with STAT3 to increase intracellular glutathione and confers resistance to oxaliplatin in colorectal cancer;Acta Pharmaceutica Sinica B;2024-09
4. Trifluridine–tipiracil plus bevacizumab versus trifluridine–tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis;BMC Cancer;2024-06-03
5. Upregulated lncRNA PRNT promotes progression and oxaliplatin resistance of colorectal cancer cells by regulating HIPK2 transcription;World Journal of Gastrointestinal Oncology;2024-04-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3